Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Sponsor: Eyconis INC.
Summary
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Official title: Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-05-19
Completion Date
2028-05
Last Updated
2026-07-07
Healthy Volunteers
No
Interventions
EYC-0305
Extended-delivery anti-VEGF
Locations (6)
Beverly Hills, CA
Beverly Hills, California, United States
Wake Forest, NC
Wake Forest, North Carolina, United States
Erie, PA
Erie, Pennsylvania, United States
Bellaire, TX
Bellaire, Texas, United States
McAllen, TX
McAllen, Texas, United States
The Woodlands, TX
The Woodlands, Texas, United States